Yahoo
NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

29.45 -0.35 (-1.17%)
At close: 4:02:59 PM EDT
29.45 0.00 (0.00%)
After hours: 4:39:33 PM EDT
Trade Pfizer on Coinbase
Dividend
PFE announced a cash dividend of $0.43 with an ex-date of Nov. 6, 2026
Chart Range Bar
Loading chart for PFE

What's happening with PFE?

10m ago
Powered by Yahoo Scout

Pfizer’s upcoming November 3, 2026, third-quarter reportwill test whether newer medicines can offset declining COVID products and patent-related revenue pressure. Recent oncology developments include a positive Phase 3 ELREXFIO result and expanded FDA approval for TALZENNA plus XTANDI, while dividend coverage and potential write-downs remain key investor concerns.

Powered by Yahoo Scout
  • Previous Close 29.80
  • Open 29.49
  • Bid 29.41 x 490000
  • Ask 29.37 x 1230000
  • Day's Range 29.22 - 29.82
  • 52 Week Range 23.62 - 30.44
  • Volume 26,224,992
  • Avg. Volume 33,964,201
  • Market Cap (intraday) 167.855B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 38.75
  • EPS (TTM) 0.76
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield 1.72 (5.77%)
  • 1y Target Est 29.26
  • Morningstar Rating Rating available with Stock Picks access

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

75,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PFE
24.38%
S&P 500 (^GSPC)
13.13%

1-Year Return

PFE
28.63%
S&P 500 (^GSPC)
12.38%

3-Year Return

PFE
18.62%
S&P 500 (^GSPC)
88.08%

5-Year Return

PFE
11.14%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 15.03B
Earnings --
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5B
10B
15B
0.0%
10.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

25.00 Low
29.26 Average
29.45 Current
36.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/9/2026
Analyst JP Morgan
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 28 -> 30

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.80%

  • Return on Assets (ttm)

    5.78%

  • Return on Equity (ttm)

    5.01%

  • Revenue (ttm)

    63.7B

  • Net Income Avi to Common (ttm)

    4.34B

  • Diluted EPS (ttm)

    0.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.7B

  • Total Debt/Equity (mrq)

    74.25%

  • Levered Free Cash Flow (ttm)

    12.49B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: